Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
Dalton Pharma Services announces the renewal of its chemistry Services Agreement with Boehringer Ingelheim (Canada) Ltd. Under the agreement Dalton will continue to provide chemistry services in support of Boehringer's pharmaceutical development programs.
Peter Pekos, President of Dalton Pharma Services, said, “The extension of our long relationship with Boehringer Ingelheim (Canada) Ltd. aligns with Dalton’s vision to support the drug development programs of leading global pharma companies. Boehringer Ingelheim’s broad commitment to research in Canada despite the world wide reductions in the research sector, demonstrates the importance of Canada as a source of creative talent.”
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.